Please use this identifier to cite or link to this item:
|Title:||Risk of second malignant neoplasms after childhood central nervous system malignant tumours: An international study||Authors:||Maule, M.
Primary central nervous system neoplasms
|Issue Date:||Apr-2008||Citation:||Maule, M., Scélo, G., Pastore, G., Brennan, P., Hemminki, K., Pukkala, E., Weiderpass, E., Olsen, J.H., Tracey, E., McBride, M.L., Brewster, D.H., Pompe-Kirn, V., Tonita, J.M., Kliewer, E.V., Chia, K.S., Jonasson, J.G., Martos, C., Magnani, C., Boffetta, P. (2008-04). Risk of second malignant neoplasms after childhood central nervous system malignant tumours: An international study. European Journal of Cancer 44 (6) : 830-839. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ejca.2008.02.012||Abstract:||Purpose: The aim of this study was to assess the risk of second malignant neoplasms (SMNs) other than central nervous system (CNS) neoplasms after childhood CNS cancer in an international multicentre study. Methods: Individual data on cases of CNS cancer in children (0-14 years) and on subsequent SMNs were obtained from 13 population-based cancer registries contributing data for different time periods in 1943-2000. Standardised incidence ratios (SIRs) with 95% confidence intervals (CI), absolute excess risk and cumulative incidence of SMNs were computed. Results: We observed 43 SMNs in 8431 CNS cancer survivors. The SIR was 10.6 (4.85-20.1) for thyroid cancer (nine cases), 2.75 (1.01-5.99) for leukaemia (six cases) and 2.47 (0.90-5.37) for lymphoma (six cases). The SIRs were highest in the first 10 years after CNS cancer diagnosis. The cumulative incidence of non-CNS SMNs was 3.30% (0.95-5.65%) within 45 years after a CNS cancer diagnosis. Within 15 years, the cumulative incidence was highest for cases diagnosed after 1980 (0.56%, 95% CI: 0.29-0.82%). Conclusion: This population-based study indicates that about one every 180 survivors of a childhood CNS cancer will develop a non-CNS SMN within the following 15 years. The excess is higher after glioma and embryonal malignant tumour than after another CNS tumour. © 2008 Elsevier Ltd. All rights reserved.||Source Title:||European Journal of Cancer||URI:||http://scholarbank.nus.edu.sg/handle/10635/109628||ISSN:||09598049||DOI:||10.1016/j.ejca.2008.02.012|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Nov 21, 2022
WEB OF SCIENCETM
checked on Nov 21, 2022
checked on Nov 24, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.